Prev Chronic Dis by Culp, MaryBeth B. & Lunsford, Natasha Buchanan
PREVENTING  CHRONIC  DISEASE
P U B L I C  H E A L T H  R E S E A R C H ,  P R A C T I C E ,  A N D  P O L I C Y 
  Volume 16, E79                                                                         JUNE 2019  
 
ORIGINAL RESEARCH
 
 
Melanoma Among Non-Hispanic Black Americans
 
MaryBeth B. Culp, MPH1; Natasha Buchanan Lunsford, PhD2
 
Accessible Version: www.cdc.gov/pcd/issues/2019/18_0640.htm
Suggested  citation  for  this  article:  Culp MB,  Lunsford NB.
Melanoma Among Non-Hispanic Black Americans. Prev Chronic
Dis 2019;16:180640. DOI: https://doi.org/10.5888/pcd16.180640.
PEER REVIEWED
Summary
What is already known on this topic?
Non-Hispanic black people have lower incidence rates of melanoma than
non-Hispanic white people; however, non-Hispanic black people are typic-
ally diagnosed at a later stage, have different proportions of histologic
types of melanoma, and have poorer survival rates than non-Hispanic
white people.
What is added by this report?
From 2011 through 2015, the histology of most melanomas diagnosed
among non-Hispanic black patients was acral lentiginous melanoma. Five-
year relative survival rates for acral lentiginous melanoma are lower than
for the predominant histologic type diagnosed among non-Hispanic white
people.
What are the implications for public health practice?
Improved education of health care providers about incidence of acral lenti-
ginous melanoma among non-Hispanic black people is needed because of
its atypical presentation and poor survival rates for this cancer.
Abstract
Introduction
Few studies have examined melanoma incidence and survival rates
among non-Hispanic black populations because melanoma risk is
lower among this group than among non-Hispanic white popula-
tions. However, non-Hispanic black people are often diagnosed
with melanoma at later stages,  and the predominant histologic
types of melanomas that occur in non-Hispanic black people have
poorer survival rates than the most common types among non-His-
panic white people.
Methods
We used the  US Cancer  Statistics  2001–2015 Public  Use  Re-
search Database to examine melanoma incidence and 5-year sur-
vival among non-Hispanic black US populations.
Results
From 2011  through  2015,  the  overall  incidence  of  melanoma
among non-Hispanic black people was 1.0 per 100,000, and incid-
ence increased with age. Although 63.8% of melanomas in non-
Hispanic black people were of unspecified histology, the most
commonly diagnosed defined histologic type was acral lentigin-
ous melanoma (16.7%). From 2001 through 2014, the relative 5-
year melanoma survival rate among non-Hispanic black people
was 66.2%.
Conclusion
Although incidence of melanoma is relatively rare among non-
Hispanic black populations,  survival rates lag behind rates for
non-Hispanic white populations. Improved public education is
needed about incidence of acral lentiginous melanoma among non-
Hispanic black people along with increased awareness among
health care providers.
Introduction
Melanoma  is  one  of  the  most  common cancers  in  the  United
States,  and  incidence  is  increasing  (1).  Most  melanomas  are
thought to be caused by a combination of exposure to ultraviolet
radiation and characteristics of sun-sensitive skin (2). People with
fair skin are generally at highest risk of melanoma; thus, recent re-
search focused primarily on white and Hispanic populations (3).
However, few studies of melanoma were conducted among non-
Hispanic black populations (4). One of these studies found that ul-
traviolet radiation is associated with skin cancer risk among black
men (5).
Skin type or complexion is a key risk factor for skin cancer (6).
Melanin, which is produced in the skin, gives skin, hair, and eyes
their color and protects the deep layers of skin cells from ultravi-
olet radiation damage (6). Skin that produces more melanin is nat-
urally darker and provides more sun protection from ultraviolet ra-
diation than light skin, which produces less melanin (6). Although
exposure to ultraviolet radiation can cause DNA damage to all
types of skin, some melanoma histology types are not attributable
to exposure (6,7). Although black men and women in the United
States are at lower risk of melanoma than white men and women,
they often have melanoma diagnosed at a later stage and have
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poorer survival as a result (4,8). Furthermore, a range of skin com-
plexions among non-Hispanic black people leads to variable risk
from ultraviolet radiation exposure (4).
Previous analyses found that melanoma histologic type and the
body site where it occurs differ by race (4,9). Acral lentiginous
melanoma (ALM), which typically presents on the palms of hands,
soles of feet, or nail beds, is associated with poor survival rates,
and a greater proportion of melanomas diagnosed among non-His-
panic  black  people  are  ALM  than  are  melanomas  diagnosed
among non-Hispanic whites (10,11). We examined melanoma in-
cidence and survival among non-Hispanic black populations in the
United States by age, stage at diagnosis, anatomic site, and histo-
logy.
Methods
We examined population-based cancer  registry incidence data
from the US Cancer Statistics (USCS) 2001–2015 Public Use Re-
search Database (12). This database combines data from the Cen-
ters for Disease Control and Prevention’s National Program of
Cancer  Registries  (NPCR)  and  from  the  National  Cancer
Institute’s Surveillance, Epidemiology, and End Results (SEER)
program,  covering the  entire  US population for  2011 through
2015. This data set excludes cancer diagnoses identified only on
autopsy or death certificate and cancers in patients of unknown
age or sex. Cancers were coded by using the International Classi-
fication of Diseases for Oncology current at the time of diagnosis
and later converted to codes in the International Classification of
Diseases for Oncology, third edition (ICD-O-3) (13). We defined
invasive melanomas of the skin as having an ICD-O-3 site code of
C440–C449 and an ICD-O-3 histology code of 8720–8790; ana-
lyses of histology data were limited to microscopically confirmed
cases, and we excluded lentigo maligna melanoma histology be-
cause of its low incidence among non-Hispanic black populations.
We limited our research to non-Hispanic black populations, ex-
cept in some instances when non-Hispanic white populations were
used as a comparison group. Non-Hispanic black and non-Hispan-
ic white race/ethnicity was identified by the demographic informa-
tion in the cancer medical case reports that were submitted to state
cancer registries. We also presented data for the US Census re-
gion in which patients lived at the time of diagnosis: Northeast,
Midwest, South, or West.
We used SEER*Stat software version 8.3.5 (National Cancer In-
stitute)  to  calculate  age-adjusted rates  per  100,000 population
(based on the 2000 US standard population), rate ratios, 95% con-
fidence intervals, average annual counts, and 5-year relative sur-
vival. Rates based on a count of fewer than 16 patients were not
reported because of concerns for rate stability (14). We limited our
analyses to the most recent 5 years of data available to present the
most current incidence rates. Rate ratios were considered to be sig-
nificant if they differed from 1 at P < .05. Survival data were taken
from NPCR registries of the 39 participating states with survival
data, which covered 81.1% of the US population for 2001 through
2014 (15). Survival rates were calculated by the actuarial method
(16). The data used in this study were publicly available and con-
tained no patient identifiable information; therefore, no institution-
al review board oversight was needed.
Results
From 2011 through 2015, 1,795 non-Hispanic black people were
diagnosed with melanomas in the United States, an average of 359
per year (incidence rate, 1.0 per 100,000) (Table 1). Rates were
similar for men and women except in the oldest age group (65 or
older), and increased with age, with the highest rates among men
aged 65 or older (5.5 per 100,000). Half (55.3%) of all melano-
mas were diagnosed at a localized stage. Women were slightly
more likely to be diagnosed at a localized stage (56.7%) than men
(53.6%). Lower extremities, including legs and feet, were the most
common anatomic sites where melanoma occurred among non-
Hispanic black people (48.2%). Patterns by anatomic site did not
vary widely by sex, although a slightly higher percentage of wo-
men than men had melanoma diagnosed on lower extremities, and
men had slightly higher percentages of melanoma diagnosed on
the head and neck and trunk than women. Most melanomas had
nonspecific histology (63.8%). Among melanomas with specific
histology, ALM were the most common (16.7%). Finally, more
than half (58.7%) of melanoma diagnoses were among people in
the southern United States compared with the Northeast (17.3%),
Midwest (13.7%), and West (10.3%).
Half (55%) of non-Hispanic black people and 78% of non-Hispan-
ic  white  people were diagnosed with melanoma at  a  localized
stage; 18% of non-Hispanic black people and 9% of non-Hispanic
white people were diagnosed with regional-stage melanoma (Fig-
ure  1).  More  non-Hispanic  black people  were  diagnosed with
melanoma with distant metastasis (16%) than non-Hispanic white
people (5%) or with unstaged melanoma (10%) than non-Hispan-
ic  white  people (8%).  Furthermore,  fewer non-Hispanic black
people than non-Hispanic white people were diagnosed with su-
perficial spreading melanoma (SSM) (non-Hispanic black, 29%;
non-Hispanic white,  79%), whereas the proportions diagnosed
with nodular melanoma were similar (non-Hispanic black, 25%;
non-Hispanic white, 19%). Although rates for ALM among non-
Hispanic black people and non-Hispanic white people were simil-
ar (0.2 per 100,000), the proportion of ALM diagnosed among
non-Hispanic black people was much higher (non-Hispanic black,
46% vs non-Hispanic white, 2%).
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Figure 1. Percentage of non-Hispanic black and non-Hispanic white population
diagnosed with melanoma, by stage at diagnosis, United States, 2011–2015.
We examined data  on 2,848 melanomas diagnosed from 2001
through 2014 (Table 2). Overall, the relative 5-year melanoma sur-
vival  rate  among non-Hispanic  black  populations  was  66.2%,
compared with 90.1% for non-Hispanic white populations. Surviv-
al decreased with age and was poorer among men (Table 2). The
earlier the stage at diagnosis, the higher the survival rate (85.8%
for localized melanoma compared with 52.8% for melanoma with
regional spread and 19.0% for melanoma with distant metastasis).
By anatomic site, melanomas diagnosed on the upper extremities
had the best survival rates (82.2%), whereas those on the lower ex-
tremities had the poorest survival rates (67.6%). Melanomas with
unknown anatomic site (not otherwise specified and other) had a
poor relative survival rate (26.2%). Survival rates were highest
among people diagnosed with SSM (91.1%), whereas rates were
poorest among those diagnosed with nodular melanoma (56.6%)
and ALM (66.1%).
Relative survival rates differed between non-Hispanic black popu-
lations and non-Hispanic white populations by sex and by stage at
diagnosis (Figure 2). Overall, regardless of stage at diagnosis, sur-
vival was lower among non-Hispanic black people than among
non-Hispanic white people. Survival for localized stage for non-
Hispanic black populations was 85.8% versus 97.5% for non-His-
panic white people; for regional stage, survival was 52.8% for
non-Hispanic black people versus 63.8% for non-Hispanic white
people and for distant stage, 19.0% for non-Hispanic black people
versus 19.8% for non-Hispanic white people. Differences by sex
showed similar patterns across all stages at diagnosis, with non-
Hispanic black men and women having lower survival rates than
non-Hispanic white men and women.
Figure 2. Five-year relative survival rate of melanoma (percentage of people
diagnosed with melanoma alive 5 years following diagnosis)  among non-
Hispanic black (NHB) and non-Hispanic white (NHW) populations, by stage at
diagnosis, United States, 2011–2015.
Discussion
Our analysis of survival data from 39 states (81.1% of the US pop-
ulation) showed lower survival rates among non-Hispanic black
people with melanoma than among non-Hispanic white people
(8,17,18). Our results are consistent with previously published
studies of non-Hispanic black populations that showed melanoma
incidence rates increasing with age (4). A smaller proportion of
non-Hispanic black people were diagnosed with melanoma in loc-
alized stages than with melanoma that had spread to distant ana-
tomic sites, as shown in a previous study in Georgia (19). Delays
in diagnosis of disease may lead to low survival rates; therefore,
these differences highlight the need for increased awareness of
melanoma in non-Hispanic black people among both the public
and health care providers and more timely diagnosis.
Previous research indicated that most melanomas among non-His-
panic black people occur on the lower limbs and hip or lower ex-
tremities, including soles of the feet (4,9). One study found that
ALM was located on the lower limbs 78.3% of the time (10). Our
results were consistent with these findings,  showing that most
melanomas among non-Hispanic black women were diagnosed on
the lower extremities (4). Furthermore, lower-extremity melano-
mas had the worst survival by anatomic site overall among both
sexes. Differences by sex in melanoma incidence and anatomic
site may indicate differences in use of sun protection, because
non-Hispanic black women report more frequent use of sun pro-
tection than do non-Hispanic black men (20,21).
Dark skin confers more protection against ultraviolet radiation
than fair skin, but skin type and skin tone can vary widely among
people of the same race/ethnicity (22). About 13% of non-Hispan-
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ic black people reported getting a sunburn in the past 12 months;
of these, 19% reported getting 4 or more sunburns in the same
period  (23).  Many non-Hispanic  black  people  perceive  them-
selves to be at lower risk of skin cancer and report using sun pro-
tection  less  frequently  than  non-Hispanic  white  people
(20,21,24,25). However, educational interventions have shown
promise in improving knowledge and use of sun protection among
people with dark skin (26).
ALM was the most common melanoma subtype diagnosed among
non-Hispanic black populations in our study. Survival is poorer
for  ALM than for  SSM, the most  common subtype diagnosed
among non-Hispanic white populations. Other studies have found
that ALM is associated with lower survival rates than other sub-
types and that the high proportion of ALM among non-Hispanic
black people may be partially responsible for poor survival out-
comes (8,10,27). Unlike other types of melanoma, ALM may not
be related to ultraviolet radiation, which may account for its high-
er incidence among non-Hispanic black populations than among
non-Hispanic white populations (4,7). One study indicated that
risk factors for ALM include previous trauma or nevi (a type of
mole)  on  soles  or  toes  and  possible  genetic  or  environmental
factors (7). More research is warranted into the causes of the ALM
subtype, which affects a high proportion of non-Hispanic black
people with melanoma.
Survival was also poor among non-Hispanic black people for nod-
ular melanoma. As with ALM, nodular melanoma is associated
with  poor  survival  and  is  often  diagnosed  in  advanced stages
(9,28). Both ALM and nodular melanoma have atypical presenta-
tion, not adhering to the “ABCD” (asymmetry, border, color, dia-
meter) guidelines for skin mole examination traditionally used to
identify melanoma (29). ALM often resembles a bruise or lesion
on the hand or foot or a bruised fingernail; nodular melanomas are
often round and symmetrical with a single color (30). One study
suggested that the atypical location of plantar melanomas is what
leads to the delay in diagnosis so that patients present with deep
tumors at late stages that are hard to treat successfully (31).
Our study had limitations. One limitation was the exclusion from
the incidence database of people with melanomas reported only on
autopsy or death certificates; however, these patients constitute
less than 5% of the database and therefore would not affect the in-
cidence rates significantly if they were included (12). Another lim-
itation is that the survival database does not cover the entire US
population; however, the 81.1% of the population included was
the best representation of survival rates available.
A strength of our analysis is its comprehensive coverage of USCS
data, which contain cancer incidence rates for the entire US popu-
lation. Furthermore, this study provides an in-depth look at melan-
oma incidence and survival rates among the non-Hispanic black
population that have not been previously reported.
Increased awareness is needed among the public and the medical
community of the prevalence of the ALM histology type and the
common anatomic sites where it occurs because of ALM’s atypic-
al presentation. Opportunities exist to provide increased education
and behavioral counseling among non-Hispanic black populations
about minimizing exposure to ultraviolet radiation to reduce skin
cancer risk and about the need for regular skin checks by medical
professionals, particularly in non-sun–exposed areas such as the
feet (32).
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Tables
Table 1. Age-Adjusted Melanoma Incidence Rates Among Non-Hispanic Black People, United States, 2011–2015a
Variable
All Male Female
Rate per
100,000
(95% CI) AACb N (%)
Rate per
100,000
(95% CI) AACb N (%)
Rate per
100,000
(95 % CI) AACb N (%)
Total 1.0 (1.0–1.1) 359 1,795 (100.0) 1.2 (1.1–1.2) 169 843 (100.0) 1.0 (0.9–1.0) 190 952 (100.0)
Age, y
0–44c 0.2 (0.2–0.3) 56 281 (15.7) 0.2 (0.2–0.2) 24 118 (14.0) 0.3 (0.2–0.3) 33 163 (17.1)
45–64 1.3c (1.2–1.4) 131 653 (36.4) 1.4c (1.2–1.5) 66 329 (39.0) 1.2c (1.1–1.3) 65 324 (34.0)
≥65 4.6c (4.3–4.9) 172 861 (48.0) 5.5c (4.9–6.1) 79 396 (47.0) 4.1c (3.7–4.4) 93 465 (48.8)
Stage at diagnosis
Localized 0.6 (0.5–0.6) 198 992 (55.3) 0.6 (0.6–0.7) 90 452 (53.6) 0.5(0.5–0.6) 108 540 (56.7)
Regional 0.2c (0.2–0.2) 65 327 (18.2) 0.2c (0.2–0.2) 33 167 (19.8) 0.2c (0.1–0.2) 32 160 (16.8)
Distant 0.2c (0.1–0.2) 59 296 (16.5) 0.2c (0.2–0.2) 29 144 (17.1) 0.2c (0.1–0.2) 30 152 (16.0)
Unstaged 0.1c (0.1–0.1) 36 180 (10.0) 0.1c (0.1–0.1) 18 80 (9.5) 0.1c (0.1–0.1) 22 100 (10.5)
Anatomic site
Head and neckc 0.1 (0.1–0.1) 34 166 (9.2) 0.1 (0.1–0.2) 18 87 (10.3) 0.1 (0.1–0.1) 16 79 (8.3)
Trunk 0.1c (0.1–0.2) 53 263 (14.7) 0.2c (0.2–0.2) 30 149 (17.7) 0.1c (0.1–0.1) 23 114 (12.0)
Upper extremity 0.2c (0.1–0.2) 56 278 (15.5) 0.2c (0.2–0.2) 28 140 (16.6) 0.1c (0.1–0.2) 28 138 (14.5)
Lower extremity 0.5c (0.5–0.5) 173 865 (48.2) 0.5c (0.4–0.5) 72 362 (42.9) 0.5c (0.5–0.6) 101 503 (52.8)
NOS and other 0.1c (0.1–0.1) 51 223 (12.4) 0.1 (0.1–0.2) 24 105 (12.5) 0.1c (0.1–0.1) 27 118 (12.4)
Histologyd
Superficial spreading
melanoma
0.1 (0.1–0.1) 37 183 (10.4) 0.1 (0.1–0.1) 17 79 (9.6) 0.1 (0.1–0.1) 21 104 (11.1)
Nodular melanoma 0.1 (0.1–0.1) 32 161 (9.1) 0.1 (0.1–0.1) 20 75 (9.1) 0.1 (0.1–0.1) 20 86 (9.2)
Acral lentiginous
melanoma
0.2c (0.2–0.2) 59 294 (16.7) 0.2c (0.2–0.2) 28 139 (16.8) 0.2c (0.1–0.2) 31 155 (16.6)
Melanoma NOS and
other
0.6c (0.6–0.7) 225 1,124 (63.8) 0.7c (0.7–0.8) 107 533 (64.5) 0.6c (0.5–0.6) 118 591 (63.1)
US Census region
Northeast 1.0 (0.9–1.1) 62 310 (17.3) 1.1 (0.9–1.3) 27 136 (16.1) 1.0 (0.8–1.1) 35 174 (18.3)
Midwest 0.8c (0.7–0.9) 49 246 (13.7) 0.8c (0.7–1.0) 23 106 (12.6) 0.8c (0.6–0.9) 28 140 (14.7)
South 1.1 (1.0–1.1) 211 1,054 (58.7) 1.2 (1.1–1.3) 101 504 (59.8) 1.0 (0.9–1.1) 110 550 (57.8)
West 1.2 (1.0–1.4) 37 185 (10.3) 1.3 (1.1–1.7) 22 97 (11.5) 1.0 (0.8–1.3) 19 88 (9.2)
Abbreviations: AAC, average annual counts; CI, confidence interval; NOS, not otherwise specified.
a Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat database (12). Rates are age-adjusted to the 2000
US standard population (19 age groups – Census P25-1130).
b Average annual counts may not sum to total because of rounding.
c This rate is significantly different (P < .05) from the rate for the reference group (first listed group) as determined by rate ratios (not shown).
d Histologic analysis was limited to microscopically confirmed cases. Lentigo maligna melanoma histology was excluded because of low numbers.
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Table 2. Relative 5-Year Survival, Melanoma Among Non-Hispanic Black People, National Program of Cancer Registries, 2001–2014a
Variable
All Male Female
N (%)
Relative Survival
(95% CI) N (%)
Relative Survival
(95% CI) N (%)
Relative Survival
(95% CI)
All ages 2,848 (100.0) 66.2%
(63.8–68.5%)
1,202 (100.0) 59.2% (55.3–62.9%) 1,646 (100.0) 71.1% (68.1–73.9%)
Age, y
0–44 579 (20.3) 75.9%
(71.8–79.5%)
227 (18.9) 64.1% (56.5–70.7%) 352 (21.4) 83.0% (78.3–86.8%)
45–64 1,069 (37.5) 68.2%
(64.6–71.4%)
503 (41.8) 59.0% (53.5–64.0%) 566 (34.4) 76.2% (71.5–80.2%)
≥65 1,200 (42.1) 58.7%
(54.3–62.9%)
472 (39.3) 56.6% (49.1–63.3%) 728 (44.2) 60.1% (54.4–65.2%)
Stage at diagnosis
Localized 1,484 (52.1) 85.8%
(82.6–88.5%)
571 (47.5) 81.5% (75.5–86.2%) 913 (55.5) 88.4% (84.3–91.4%)
Regional 596 (20.9) 52.8%
(47.6–57.8%)
265 (22.0) 46.4% (38.6–53.8%) 331 (20.1) 57.7% (50.6–64.1%)
Distant 444 (15.6) 19.0%
(14.8–23.7%)
219 (18.2) 15.0% (9.8–21.1%) 225 (13.7) 22.3% (16.1–29.2%)
Unstaged 324 (11.4) 63.2%
(55.9–69.7%)
147 (12.2) 57.4% (46.0–67.2%) 177 (10.8) 67.2% (58.2–74.7%)
Anatomic site
Head and neck 296 (10.4) 69.7%
(62.2–76.1%)
153 (12.7) 62.2% (51.2–71.5%) 143 (8.7) 77.6% (66.7–85.3%)
Trunk 413 (14.5) 77.2%
(71.2–82.1%)
200 (16.6) 76.0% (66.4–83.2%) 213 (12.9) 77.8% (69.7–84.0%)
Upper extremity 380 (13.3) 82.2%
(75.8–87.1%)
161 (13.4) 81.5% (70.5–88.7%) 219 (13.3) 82.9% (74.3–88.8%)
Lower extremity 1,413 (49.6) 67.6%
(64.0–70.9%)
532 (44.3) 57.2% (51.1–62.9%) 881 (53.5) 73.5% (69.1–77.3%)
NOS and other 346 (12.1) 26.2%
(20.9–31.8%)
156 (13.0) 16.3% (10.2–23.7%) 190 (11.5) 33.9% (26.1–41.9%)
Histologyb
Superficial spreading
melanoma
321 (11.4) 91.1%
(83.9–95.2%)
134 (11.3) 92.7% (75.8–98.0%) 187 (11.5) 90.0% (81.1–94.9%)
Nodular melanoma 236 (8.4) 56.6%
(47.8–64.5%)
105 (8.9) 49.9% (37.2–61.4%) 131 (8.1) 62.3% (50.0–72.5%)
Acral lentiginous melanoma 452 (16.1) 66.1%
(59.2–72.1%)
174 (14.7) 54.7% (43.0–65.0%) 278 (17.1) 72.6% (64.0–79.5%)
Melanoma NOS and other 1,801 (64.1) 62.1%
(59.1–64.9%)
770 (65.1) 54.2% (49.5–58.7%) 1,031 (63.4) 67.6% (63.8–71.1%)
Abbreviations: CI, confidence interval; NOS, not otherwise specified.
a Relative 5-year survival refers to the percentage of people with diagnosed melanoma alive 5 years following diagnosis compared with the general population.
Source: National Program of Cancer Registries SEER*Stat database (15).
b Histologic analysis was limited to microscopically confirmed cases. Lentigo maligna melanoma histology was excluded because of low case counts.
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